within Pharmacolibrary.Drugs.ATC.R;

model R03BA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.11,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 9 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 0,            
    Vdp             = 0.003,
    k12             = 9,
    k21             = 9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03BA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Budesonide is a synthetic corticosteroid with potent glucocorticoid activity. It is commonly used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis). It is approved and widely used in inhaled, oral, and rectal formulations due to its high first-pass metabolism, which minimizes systemic side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Gupta, SK, et al., &amp; Song, IH (2022). Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis. <i>Journal of pediatric gastroenterology and nutrition</i> 75(2) 186–191. DOI:<a href=\"https://doi.org/10.1097/MPG.0000000000003482\">10.1097/MPG.0000000000003482</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35666852/\">https://pubmed.ncbi.nlm.nih.gov/35666852</a></p></li><li><p>Tambucci, R, et al., &amp; De Angelis, P (2023). Oral Viscous Budesonide in Children With Eosinophilic Esophagitis After Repaired Esophageal Atresia: A Clinical Trial. <i>Journal of pediatric gastroenterology and nutrition</i> 77(2) 249–255. DOI:<a href=\"https://doi.org/10.1097/MPG.0000000000003830\">10.1097/MPG.0000000000003830</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37195886/\">https://pubmed.ncbi.nlm.nih.gov/37195886</a></p></li><li><p>Simeoli, R, et al., &amp; Goffredo, BM (2024). Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia. <i>Pharmaceutics</i> 16(7) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics16070872\">10.3390/pharmaceutics16070872</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39065569/\">https://pubmed.ncbi.nlm.nih.gov/39065569</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03BA02;
